Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 19, 2019 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.; Arcturus Therapeutics Holdings Inc.

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics$30 million of upfront payments...
June 17, 2019 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer

NOVATO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and...
May 31, 2019 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at Upcoming Investor Conferences

NOVATO, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and...
May 29, 2019 16:01 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award

NOVATO, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and...
May 10, 2019 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference

NOVATO, Calif., May 10, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and...
May 06, 2019 16:01 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update

Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States NOVATO, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Ultragenyx...
April 30, 2019 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Host Conference Call for First Quarter 2019 Financial Results and Corporate Update

NOVATO, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and...
April 16, 2019 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces UX007 Granted Fast Track Designation and Rare Pediatric Disease Designation by U.S. FDA for Treatment of Long-Chain Fatty Acid Oxidation Disorders

NOVATO, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and...
April 11, 2019 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 17 in New York

NOVATO, Calif., April 11, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and...
March 26, 2019 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Approval of Crysvita® (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children

NOVATO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and...